Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Collegium Pharmaceutical Inc    COLL

COLLEGIUM PHARMACEUTICAL INC (COLL)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/12/2018 02/13/2018 02/14/2018 02/15/2018 02/16/2018 Date
23.62(c) 24.37(c) 25.5(c) 25.36(c) 25.9(c) Last
1 908 695 392 435 506 444 400 937 413 769 Volume
+8.50% +3.18% +4.64% -0.55% +2.13% Change
More quotes
Financials ($)
Sales 2017 27,6 M
EBIT 2017 -75,2 M
Net income 2017 -74,7 M
Finance 2017 107 M
Yield 2017 -
Sales 2018 294 M
EBIT 2018 3,81 M
Net income 2018 -25,1 M
Finance 2018 76,0 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 26,6x
EV / Sales2018 2,61x
Capitalization 843 M
More Financials
Company
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of next-generation abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases.Its products... 
Sector
Pharmaceuticals
Calendar
03/13Earnings Release
More about the company
Surperformance© ratings of Collegium Pharmaceutical I
Trading Rating : Investor Rating :
More Ratings
Latest news on COLLEGIUM PHARMACEUTICAL I
01/11COLLEGIUM PHARMACEUTICAL : Announces Closing of Agreement to License Rights to C..
AQ
01/11DEPOMED : Announces Closing of NUCYNTA Commercialization Agreement With Collegiu..
AQ
01/10DEPOMED,INC. (NASDAQ : DEPO) Files An 8-K Other Events
AQ
01/10COLLEGIUM PHARMACEUTICAL,INC. (NASDA : COLL) Files An 8-K Entry into a Material ..
AQ
01/10Collegium Announces Closing of Agreement to License Rights to Commercialize N..
GL
2017COLLEGIUM PHARMACEUTICAL,INC. (NASDA : COLL) Files An 8-K Termination of a Mater..
AQ
2017COLLEGIUM PHARMACEUTICAL, INC : Termination of a Material Definitive Agreement (..
AQ
2017Collegium to Participate in the Guggenheim Securities 5th Annual Boston Healt..
GL
2017DEPOMED : Announces NUCYNTA Commercialization Agreement with Collegium Pharmaceu..
AQ
2017COLLEGIUM PHARMACEUTICAL : Grunenthal GmbH - New partnership for the commerciali..
AQ
More news
Sector news : Pharmaceuticals - NEC
01:17pNOVARTIS : Correction to Novartis CEO story
DJ
12:40pStronger European Earnings Augur More M&A, Higher Dividends
DJ
11:17aReckitt earnings miss forecast as challenges continue
RE
09:15aAstraZeneca's immunotherapy drug wins key lung cancer approval
RE
08:37aASTRAZENECA : Cell Lung Cancer Treatment Imfinzi Gets FDA Approval
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
09:31aCollegium Pharmaceutical $COLL Lifted to Buy at BidaskClub  
02/18$FLCR down here is like stealing candy from a baby $AAPL $NOK $INTC $ZN.. 
02/16$FLCR down here is like stealing candy from a baby $AAPL $NOK $INTC $ZN..
1
02/16Collegium Pharmaceutical $COLL Earning Somewhat Positive Press Coverage, Anal.. 
02/16Collegium Pharmaceutical $COLL Given New $32.00 Price Target at Jefferies Gro.. 
More tweets
Qtime:71
News from SeekingAlpha
02/12PREMARKET GAINERS AS OF 9 : 05 am (02/12/2018) 
02/12Purdue's retrenchment from opioid promotion buoys Collegium, up 14% premarket 
02/12WALL STREET BREAKFAST : Infrastructure Details Coming Today 
02/11OxyContin maker stops promoting opioids 
02/06ROTY EDITION 1 VOLUME 76 : How To Deal With Market Selloffs And Spring Cleaning .. 
Chart COLLEGIUM PHARMACEUTICAL I
Duration : Period :
Collegium Pharmaceutical I Technical Analysis Chart | COLL | US19459J1043 | 4-Traders
Technical analysis trends COLLEGIUM PHARMACEUTICAL I
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 29,4 $
Spread / Average Target 14%
EPS Revisions
Managers
NameTitle
Michael Thomas Heffernan Chairman, President & Chief Executive Officer
Joseph J. Ciaffoni Chief Operating Officer & Executive Vice President
Paul Brannelly CFO, Principal Accounting Officer & Executive VP
Alison Fleming Chief Technology Officer
Michael DeGeorge Vice President-Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
COLLEGIUM PHARMACEUTICAL INC38.14%826
JOHNSON & JOHNSON-7.19%352 552
NOVARTIS-3.37%224 301
PFIZER-2.84%212 857
ROCHE HOLDING LTD.-9.37%210 327
MERCK AND COMPANY-0.50%149 572